关注
Thomas F Gajewski
Thomas F Gajewski
在 medicine.bsd.uchicago.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Innate and adaptive immune cells in the tumor microenvironment
TF Gajewski, H Schreiber, YX Fu
Nature immunology 14 (10), 1014-1022, 2013
38762013
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
A Sivan, L Corrales, N Hubert, JB Williams, K Aquino-Michaels, ZM Earley, ...
Science 350 (6264), 1084-1089, 2015
35332015
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
S Spranger, R Bao, TF Gajewski
Nature 523 (7559), 231-235, 2015
25582015
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
V Matson, J Fessler, R Bao, T Chongsuwat, Y Zha, ML Alegre, JJ Luke, ...
Science 359 (6371), 104-108, 2018
25142018
Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells
S Spranger, RM Spaapen, Y Zha, J Williams, Y Meng, TT Ha, TF Gajewski
Science translational medicine 5 (200), 200ra116-200ra116, 2013
18152013
STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors
L Deng, H Liang, M Xu, X Yang, B Burnette, A Arina, XD Li, H Mauceri, ...
Immunity 41 (5), 843-852, 2014
17782014
Tumor and microenvironment evolution during immunotherapy with nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ...
Cell 171 (4), 934-949. e16, 2017
17592017
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors
SR Woo, MB Fuertes, L Corrales, S Spranger, MJ Furdyna, MYK Leung, ...
Immunity 41 (5), 830-842, 2014
16242014
Loss of PTEN promotes resistance to T cell–mediated immunotherapy
W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ...
Cancer discovery 6 (2), 202-216, 2016
13962016
Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity
L Corrales, LH Glickman, SM McWhirter, DB Kanne, KE Sivick, ...
Cell reports 11 (7), 1018-1030, 2015
13082015
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ...
Cell 170 (6), 1109-1119. e10, 2017
12792017
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
MB Fuertes, AK Kacha, J Kline, SR Woo, DM Kranz, KM Murphy, ...
Journal of Experimental Medicine 208 (10), 2005-2016, 2011
12582011
Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy
S Spranger, D Dai, B Horton, TF Gajewski
Cancer cell 31 (5), 711-723. e4, 2017
12142017
Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones.
TF Gajewski, FW Fitch
Journal of immunology (Baltimore, Md.: 1950) 140 (12), 4245-4252, 1988
12071988
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
H Harlin, Y Meng, AC Peterson, Y Zha, M Tretiakova, C Slingluff, ...
Cancer research 69 (7), 3077-3085, 2009
11562009
Helper T cell differentiation is controlled by the cell cycle
JJ Bird, DR Brown, AC Mullen, NH Moskowitz, MA Mahowald, JR Sider, ...
Immunity 9 (2), 229-237, 1998
10561998
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C Blank, I Brown, AC Peterson, M Spiotto, Y Iwai, T Honjo, TF Gajewski
Cancer research 64 (3), 1140-1145, 2004
10282004
Cancer classification using the Immunoscore: a worldwide task force
J Galon, F Pagès, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, ...
Journal of translational medicine 10, 1-10, 2012
9582012
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank, TF Gajewski, A Mackensen
Cancer Immunology, Immunotherapy 54, 307-314, 2005
8202005
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double …
GV Long, R Dummer, O Hamid, TF Gajewski, C Caglevic, S Dalle, ...
The Lancet Oncology 20 (8), 1083-1097, 2019
7002019
系统目前无法执行此操作,请稍后再试。
文章 1–20